What is the recommended diagnostic workup and treatment plan for sarcoidosis?

Sarcoidosis: Diagnostic Workup and Treatment

For suspected sarcoidosis, establish diagnosis through compatible clinical presentation, nonnecrotizing granulomas on biopsy (except in classic presentations like Löfgren's syndrome), and exclusion of alternative causes, then treat only when there is risk of organ damage, mortality, or significant quality of life impairment—starting with glucocorticoids for most organ involvement except pulmonary disease where methotrexate is now equally effective as first-line therapy. 1, 2

Diagnostic Workup Algorithm

Clinical Presentation Assessment

The diagnosis rests on three pillars: compatible clinical presentation, histopathologic confirmation, and exclusion of alternatives 1. Look specifically for:

• Classic presentations that may NOT require biopsy 1:

  • Löfgren's syndrome (bilateral hilar lymphadenopathy, erythema nodosum, arthritis)
  • Lupus pernio
  • Heerfordt's syndrome (uveitis, parotid enlargement, facial palsy, fever)
  • These patients require close clinical follow-up but can skip lymph node sampling

• Respiratory symptoms: Ongoing dyspnea and dry cough in young to middle-aged adults 3

• Constitutional symptoms: Fever, unintentional weight loss, fatigue 3

Mandatory Baseline Testing

Strong recommendation 1:

• Serum calcium (only strong recommendation in the guidelines)

Conditional recommendations for screening 1, 4:

• Serum creatinine (even without renal symptoms)
• Consider 24-hour urinary calcium excretion at diagnosis 4
• Electrocardiogram or 24-hour Holter monitoring (screen for cardiac involvement)
• Ophthalmological examination
• Pulmonary function tests
• Chest imaging (CT increasingly preferred over plain radiography) 5

Histopathologic Confirmation

When biopsy IS needed 1, 6:

• Cases without classic presentations listed above
• Diagnostic uncertainty
• Multidisciplinary team should guide decision

Biopsy approach 6:

• Endobronchial ultrasound-guided fine needle aspiration (EBUS-FNA) for mediastinal lymph nodes (preferred method in Korea and increasingly worldwide) 7
• Endoscopic ultrasound for accessible nodes
• Transbronchial biopsy for parenchymal involvement
• Choice depends on extent of mediastinal versus parenchymal disease

Critical pathology finding: Noncaseating, non-necrotizing epithelioid granulomas 7

Exclusion of Alternatives

Must rule out 8, 9, 7:

• Tuberculosis (especially critical in endemic areas like Korea) 7
• Infections (fungal, mycobacterial)
• Drug-induced granulomatosis
• Malignancies
• Vasculitis
• Inborn errors of immunity

Treatment Algorithm

Decision to Treat

Do NOT treat all patients 8, 7. Treatment is indicated only when:

• Risk of death or organ failure exists
• Progressive organ dysfunction
• Significant quality of life impairment
• Symptomatic disease affecting critical organs

Avoid treatment in Löfgren's syndrome 8—spontaneous resolution is expected

First-Line Treatment by Organ System

Pulmonary Sarcoidosis

Major paradigm shift: Methotrexate is now equally effective as prednisone for first-line treatment 2, 9.

• Option 1: Methotrexate 10-15 mg once weekly 2
• Option 2: Prednisone/prednisolone initial 20 mg daily, maintenance 5-10 mg daily to every other day 2
• Rationale: Methotrexate avoids cumulative corticosteroid toxicity (diabetes, hypertension, weight gain, osteoporosis, cataracts, mood changes) 2

Monitoring for methotrexate: CBC, hepatic and renal function; avoid in significant renal failure 2

Cardiac Sarcoidosis

Strong recommendation: Use glucocorticoids (with or without other immunosuppressives) for functional cardiac abnormalities including heart block, dysrhythmias, or cardiomyopathy 2

This is one of only two strong recommendations in the treatment guidelines, reflecting the mortality risk.

Neurosarcoidosis

Strong recommendation: Glucocorticoids for clinically significant neurosarcoidosis 2

Escalation pathway:

1. Glucocorticoids first-line
2. Add methotrexate if continued disease 2
3. Add infliximab if disease persists despite glucocorticoids + second-line agent (methotrexate, azathioprine, or mycophenolate mofetil) 2

Cutaneous Sarcoidosis

• Oral glucocorticoids for cosmetically important active lesions not controlled by local treatment 2
• Add infliximab if continued disease despite glucocorticoids and/or other immunosuppressives 2

Second-Line and Refractory Disease

For pulmonary disease with inadequate response or unacceptable steroid side effects 2:

• Add methotrexate to improve/preserve FVC and quality of life

For high-risk patients with continued disease despite initial therapy 2:

• Add infliximab 3-5 mg/kg initially, at 2 weeks, then every 4-6 weeks 2
• Critical monitoring: Screen for prior TB, monitor for allergic reactions (can be life-threatening), contraindicated in severe CHF, prior malignancy, demyelinating disease, active TB, deep fungal infections 2
• Alternative: Adalimumab 40 mg every 1-2 weeks (less toxic than infliximab) 2

Other second-line options 2:

• Leflunomide 10-20 mg daily
• Azathioprine 50-250 mg daily
• Mycophenolate mofetil 500-1500 mg twice daily (less experience in sarcoidosis)

Special Situations

Sarcoidosis-Associated Fatigue

Stepwise approach 2:

1. First: Pulmonary rehabilitation program and/or inspiratory muscle strength training for 6-12 weeks
2. If fatigue not related to disease activity: Consider D-methylphenidate or armodafinil for 8 weeks to test effect and tolerability

Small-Fiber Neuropathy

No recommendations made due to insufficient evidence 2

Critical Pitfalls

1. Never start treatment before histologic confirmation except in classic presentations (Löfgren's, lupus pernio, Heerfordt's) 8
2. Avoid systemic corticosteroids in Löfgren's syndrome—spontaneous resolution expected 8
3. Screen for tuberculosis before starting immunosuppression, especially infliximab 2, 7
4. Monitor for infliximab allergic reactions—can be life-threatening 2
5. Not all sarcoidosis requires treatment—approximately two-thirds show spontaneous remission 7
6. Cumulative corticosteroid toxicity is substantial—consider methotrexate as first-line for pulmonary disease 2, 9
7. Cardiac and neurologic involvement require aggressive treatment due to mortality risk 2

Prognosis Context

Approximately 10-30% develop chronic/progressive disease; mortality rate is 3-5% 7. One-third develops chronic disease with increased risk of organ failure or death 9. This variable natural history underscores the importance of treating only when necessary while being aggressive with life-threatening organ involvement.